|
|
 |
|
INTENDED AUDIENCE: Physicians, Physician assistants, nurses, nurse practitioners and advanced practice nurses, pharmacists and dentists involved in the treatment and care of persons infected with the HIV virus.
EDUCATIONAL OBJECTIVES: Upon completion of this monograph, the participant should be able to:
- Understand the basics of the clinical pharmacology of the reverse transcriptase inhibitors as well as the protease inhibitors including their adverse effects.
- Understand combinations of HAART and how to use them in the treatment of HIV disease.
- Understand the side effects, long-term toxicities, including metabolic complications of HAART medications, and how to avoid and circumvent these.
- Understand adherence, issues of pill burden in a disease where treatment is life-long; understand resistance and the role of adherence in improving outcomes while decreasing emergence of resistance strains.
- Be able to educate HIV-infected patients and to counsel them on HAART regimens they are receiving for this life-long disease.
ACCREDITATION: this material, at the point of presentation, will be approved for continuing education credit by the American Council on Medical Education (CME), the American Council of Nursing Education and the American Council of Pharmaceutical Education (ACPE).
DISCLOSURE
In accordance with the Accreditation Council for Continuing Medical and Pharmaceutical education Standards for Commercial Support, the Course Director for this activity has been asked to complete a disclosure form. Disclosures are described below:
Dr. Tina Edmunds-Ogbuokiri, Pharm.D., FASCP
Associate Professor of Clinical Pharmacy, Xavier University of Louisiana College of Pharmacy and Consultant Clinical Pharmacist, HIV Outpatient Clinic, 136 S. Roman Street, Medical Center of Louisiana at New Orleans.
Grant/Research Support: National Minority AIDS Education and Training Center, Funding Agency Grant Number: 1H4A HA 00066-01. |
|
|
Transcriptase 
